+1,180.9%
AXON vs GSK
+101.6%
+1,079.3%
-65.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.1% | +2.4% | -5.5% | -3.6% |
| 7D | -28.7% | +4.9% | -33.6% | -29.3% |
| 30D | -28.3% | +10.8% | -39.1% | -29.6% |
| 3M | -46.9% | -1.8% | -45.1% | -46.8% |
| 6M | -24.9% | +4.1% | -29.0% | -25.5% |
| YTD | -46.6% | +7.9% | -54.5% | -47.8% |
| 1Y | -49.7% | +14.4% | -64.1% | -51.4% |
| 3Y | +40.6% | +68.1% | -27.5% | +20.5% |
| 5Y | +71.9% | +47.7% | +24.2% | +51.3% |
| 10Y | +1,180.9% | +100.5% | +1,080.4% | +990.9% |
| All | +1,180.9% | +101.6% | +1,079.3% | +990.9% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling